Veradermics Inc. (NYSE: MANE) reported 12-month data from a Phase 2/3 clinical trial of VDPHL01, an oral extended-release minoxidil formulation for male pattern hair loss. Shares rose 2.3% in Monday trade, according to Investing.com.

The company said participants on twice-daily treatment saw non-vellus hair count increase by 43.9 hairs/cm² from baseline at Month 12. Participants on once-daily treatment saw an increase of 29.7 hairs/cm². Veradermics described the twice-daily arm as showing deepening of hair growth and the once-daily arm as showing maintenance.

In Study '302' Part B, 89.1% of twice-daily participants and 79.8% of once-daily participants reported visible improvement in hair coverage on the Androgenetic Alopecia Impact Rating Scale. The company said 68.0% of twice-daily participants and 48.4% of once-daily participants achieved "improved" or "much improved" hair coverage.

The trial enrolled 519 patients who received VDPHL01 8.5mg once daily, VDPHL01 8.5mg twice daily, or placebo for six months. Placebo patients then crossed over to VDPHL01 for the remaining six months.

Veradermics reported that the treatment was generally well tolerated through Month 12. The company said it saw no treatment-related serious adverse events, no adverse events of special interest of cardiac origin, and no new safety signals. It also reported no discontinuations due to adverse events between Month 6 and Month 12 in the continued treatment group.

The company previously reported positive topline results from Part A of Study '302' and Phase 3 Study '304'. It expects to announce data from its female pattern hair loss Phase 2/3 trial in the first half of 2027.